{"product_id":"metabolic-syndrome-isbn-9780470343425","title":"Metabolic Syndrome","description":"\u003cb\u003eMETABOLIC SYNDROME\u003c\/b\u003e \u003cp\u003e\u003cb\u003eA comprehensive look at the fight against the metabolic syndrome epidemic \u003c\/b\u003e  \u003c\/p\u003e\u003cp\u003eIncreasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. \u003ci\u003eMetabolic Syndrome: Underlying Mechanisms and Drug therapies\u003c\/i\u003e extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of molecular mechanisms and drug pharmacology for pharmaceutical scientists.  \u003c\/p\u003e\u003cp\u003eThe book starts by examining the physiology of metabolic tissues under normal and disease states, followed by discussions of metabolic diseases and clinical complications. The development of drug therapies based on emerging science is then covered extensively. In addition, there is an in-depth look into the metabolic pathways and dysfunctions in metabolic disease, especially type 2 diabetes and lipid disorders. Finally, a chapter is devoted to past successes and failures in metabolic drug discovery as well as an outlook on future development and challenges.  \u003c\/p\u003e\u003cp\u003eDivided into four parts, the book: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAddresses important metabolic syndrome basics at the psychological level and metabolic abnormalities at the tissue and pathway levels\u003c\/li\u003e \u003cli\u003eCovers the identification of pathways and molecular targets for the development of anti-diabetic therapies\u003c\/li\u003e \u003cli\u003eDetails pharmaceutical industry approach to solving metabolic and obesity related problems\u003c\/li\u003e \u003cli\u003eDescribes drug therapies and their limitations and complications, offering a “lessons learned” from existing treatments\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWith a clear organization and extensive collection of references, the book is a user-friendly and unique tool for scientists in a variety of scientific disciplines in the pharmaceutical and biotechnology industries. \u003c\/p\u003e\u003cp\u003eIntroduction ix\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart One The Physiology of Metabolic Tissues Under Normal and Disease States\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Gut as an Endocrine Organ: the Role of Nutrient Sensing in Energy Metabolism 3\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2. Central Glucose Sensing and Control of Food Intake and Energy Homeostasis 29\u003cbr\u003e \u003ci\u003eLourdes Mounien and Bernard Thorens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3. Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus 53\u003cbr\u003e \u003ci\u003eTaly Meas and Pierre-Jean Guillausseau\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4. Adipokine Production by Adipose Tissue: A Novel Target for Treating Metabolic Syndrome and its Sequelae 73\u003cbr\u003e \u003ci\u003eVanessa DeClercq, Danielle Stringer, Ryan Hunt, Carla G. Taylor, and Peter Zahradka\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5. Hepatic Metabolic Dysfunctions in Type 2 Diabetes: Insulin Resistance and Impaired Glucose Production and Lipid Synthesis 133\u003cbr\u003e \u003ci\u003eRuojing Yang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6. Energy Metabolism in Skeletal Muscle and its Link to Insulin Resistance 157\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart Two Metabolic Diseases and Current Therapies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7. Mechanisms and Complications of Metabolic Syndrome 179\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL 199\u003cbr\u003e \u003ci\u003eMargrit Schwarz and Jae B. Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9. Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery 235\u003cbr\u003e \u003ci\u003eDevan Marar, Shobha H. Ganji, Vaijinath S. Kamanna, and Moti L. Kashyap\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10. Current Antidiabetic Therapies and Mechanisms 253\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart Three Drug Targets for Antidiabetic Therapies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11. GLP-1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies 281\u003cbr\u003e \u003ci\u003eRemy Burcelin, Cendrine Cabou, Christophe Magnan, and Pierre Gourdy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12. Dipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes 327\u003cbr\u003e \u003ci\u003eC.H.S. McIntosh, S.-J. Kim, R.A. Pederson, U. Heiser, and H.-U. Demuth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13. Sodium Glucose Cotransporter 2 Inhibitors 359\u003cbr\u003e \u003ci\u003eMargaret Ryan and Serge A. Jabbour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14. Fibroblast Growth Factor 21 as a Novel Metabolic Regulator 377\u003cbr\u003e \u003ci\u003eRadmila Micanovic, James D. Dunbar, and Alexei Kharitonenkov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15. Sirtuins as Potential Drug Targets for Metabolic Diseases 391\u003cbr\u003e \u003ci\u003eQiang Tong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16. 11β-Hydroxysteroid Dehydrogenase Type 1 as a Therapeutic Target for Type 2 Diabetes 423\u003cbr\u003e \u003ci\u003eClarence Hale and David J. St. Jean, Jr.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17. Monoclonal Antibodies for the Treatment of Type 2 Diabetes: A Case Study with Glucagon Receptor Blockade 459\u003cbr\u003e \u003ci\u003eHai Yan, Wei Gu, and Murielle Veniant-Ellison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart Four Lessons Learned and Future Outlook\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18. Drug Development for Metabolic Diseases: Past, Present and Future 471\u003cbr\u003e \u003ci\u003eMinghan Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 489 \u003c\/p\u003e \"This is an outstanding addition to the current body of work on the metabolic syndrome. I thought it particularly exhaustive in its review of the literature, making it an excellent resource for scouring the primary literature, and found the duality of current and future treatment approaches particularly insightful.\" (Doody's, 21 October 2011)  \u003cp\u003e \"The book offers a comprehensive and in-depth view of energy metabolism, metabolic tissues and pathways, molecular mechanism-based drug discovery and clinical implications.\" (Pharmiweb, 1 March 2011)\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMINGHAN “MING” WANG, P\u003csmall\u003eH\u003c\/small\u003eD\u003c\/b\u003e is Director and head of a metabolism group in Metabolic Disorders Research at Amgen. He has authored over forty publications and is a regular speaker at drug discovery conferences.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eA comprehensive look at the fight against the metabolic syndrome epidemic \u003c\/b\u003e \u003c\/p\u003e \u003cp\u003eIncreasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. \u003ci\u003eMetabolic Syndrome: Underlying Mechanisms and Drug therapies\u003c\/i\u003e extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of molecular mechanisms and drug pharmacology for pharmaceutical scientists.  \u003c\/p\u003e\u003cp\u003eThe book starts by examining the physiology of metabolic tissues under normal and disease states, followed by discussions of metabolic diseases and clinical complications. The development of drug therapies based on emerging science is then covered extensively. In addition, there is an in-depth look into the metabolic pathways and dysfunctions in metabolic disease, especially type 2 diabetes and lipid disorders. Finally, a chapter is devoted to past successes and failures in metabolic drug discovery as well as an outlook on future development and challenges.  \u003c\/p\u003e\u003cp\u003eDivided into four parts, the book: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAddresses important metabolic syndrome basics at the psychological level and metabolic abnormalities at the tissue and pathway levels\u003c\/li\u003e \u003cli\u003eCovers the identification of pathways and molecular targets for the development of anti-diabetic therapies\u003c\/li\u003e \u003cli\u003eDetails pharmaceutical industry approach to solving metabolic and obesity related problems\u003c\/li\u003e \u003cli\u003eDescribes drug therapies and their limitations and complications, offering a “lessons learned” from existing treatments\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWith a clear organization and extensive collection of references, the book is a user-friendly and unique tool for scientists in a variety of scientific disciplines in the pharmaceutical and biotechnology industries.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989610447077,"sku":"NP9780470343425","price":171.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470343425.jpg?v=1761784798","url":"https:\/\/k12savings.com\/products\/metabolic-syndrome-isbn-9780470343425","provider":"K12savings","version":"1.0","type":"link"}